Related Experiment Video
Updated: Apr 14, 2026
06:09
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
23.1K
LRRK2 mutations and neurotoxicant susceptibility
Jang-Won Lee1, Jason R Cannon2
1School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA.
Experimental Biology and Medicine (Maywood, N.J.)
|April 19, 2015
Summary
Genetic and environmental factors influence Parkinson's disease (PD). Leucine-rich repeat kinase 2 (LRRK2) mutations, a common cause of hereditary PD, may affect sensitivity to neurotoxicants, as explored in animal models.
Area of Science:
- Neuroscience
- Genetics
- Environmental Health
Background:
- Parkinson's disease (PD) pathogenesis involves complex genetic and environmental interactions, though poorly understood.
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are the leading genetic cause of hereditary PD.
- Incomplete penetrance of LRRK2 mutations suggests additional contributing factors.
Purpose of the Study:
- To critically review current data on the role of LRRK2 mutations in mediating neurotoxicity.
- To explore how LRRK2 influences sensitivity to environmental neurotoxicants in PD models.
Main Methods:
- Literature review of existing studies.
- Analysis of data from animal models investigating LRRK2 and neurotoxicant interactions.
Main Results:
- LRRK2 mutations are implicated in modulating an individual's susceptibility to environmental neurotoxicants.
- Animal models provide insights into the mechanisms by which LRRK2 affects neurotoxicity.
Conclusions:
- Understanding LRRK2's role in neurotoxicity is crucial for elucidating PD pathogenesis.
- Further research is needed to fully grasp the interplay between LRRK2, environment, and PD development.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
127
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
01:24Drug Toxicity: Risk factors
210
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
210